Nordec Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -94.14%
- Profit Growth -67.10%
- Ebitda 213.98%
- Net Worth 16.21%
- Total Assets -82.01%
About Nordec Laboratories
Nordec Laboratories Private Limited (NLPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 February 2020 (Four years and 11 months 14 days old ). Its registered office is in North West Delhi, Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kishan Mohan and Nidhi Aggarwal serve as directors at the Company.
Company Details
-
Location
North West Delhi, Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24304DL2020PTC362154
-
Company No.
362154
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Feb 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Nordec Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nidhi Aggarwal
|
Director | 20-Feb-2020 | Current |
|
Kishan Mohan
|
Director | 20-Feb-2020 | Current |
Financial Performance of Nordec Laboratories.
Nordec Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 94.14% decrease. The company also saw a substantial fall in profitability, with a 67.1% decrease in profit. The company's net worth Soared by an impressive increase of 16.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nordec Laboratories?
Unlock access to Nordec Laboratories's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Normon Labs LlpKishan Mohan is a mutual person
-
Kalkyn Pharma Llp
Kishan Mohan is a mutual person
-
Hexiachem Llp
Kishan Mohan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nordec Laboratories?
Unlock and access historical data on people associated with Nordec Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nordec Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nordec Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
